ClinicalTrials.gg
RecruitingNCT06122090Updated May 3, 2024

Treatment of Hypopigmented Scars With Bimatoprost

A Phase 2 interventional study of Bimatoprost and Saline in Scars, Hypopigmented Scar and Hypopigmented Skin, sponsored by Medstar Health Research Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Primary conditionCicatrix, HypertrophicRegistry: CicatrixReclassifiedWhy we changed it
Registry
Cicatrix — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cicatrix, Hypertrophic
Why
  1. The study's listed conditions name Cicatrix, Hypertrophic, a narrower term within Cicatrix.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Medstar Health Research Institute · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients who have hypo-pigmented burn scar will have two scars chosen and randomized to treated scar and control scar. The subject will then have both scars treated with fractional ablative CO2 laser (FLSR). The treated scar will have bimatoprost delivered through the laser channels, while the control will have the vehicle (normal saline) only delivered. The treatment will continue for 14 days with twice daily application. The scars will then be monitored at a 2-week follow-up visit where levels of melanin will be evaluated. Tissue punch biopsies will also be used to evaluate the mechanism of action of bimatoprost. Treatment will occur for 6 sessions at 4-6 week intervals including follow- up visits and evaluations.

Read the detailed description

If the subject agrees to take part in this study, the subject's scars will be looked at and the investigators will pick two sites that will be involved in the research. Each scar will be "randomized" into one of two study groups. One scar will be the treatment group which will be treated with standard of care therapies plus the fractionated ablative CO2 laser and topical bimatoprost drug. The other scar will be the control group which will be treated with standard of care therapies, the fractional ablative CO2 laser, and a control solution. Randomization means that either of the two scars has an equal chance of being designated as the treatment or control group. It is like flipping a coin. Neither the subject nor the investigators will choose what scar will be treated or control. Each half has a 50% chance of being placed in either group.

This study will take place in an outpatient setting. Subjects will not be admitted to the hospital overnight. Patients who enter the study will need to be able to follow up for regular appointments with the burn department.

Before the investigators start the laser treatment, the subject will come in for a pre-treatment visit where the investigators will collect information about the scars such as pictures, non-invasive probes, non-invasive imaging (ultrasound), and questionnaires filled out by the subject and the provider. These questionnaires will be related to the symptoms and appearance of scars. The questionnaires will also evaluate overall psychological health. There will also be a blood draw where less than 2 tablespoons of blood are collected. It is estimated this visit will take less than 1 hour. The investigators will also collect information from the medical record about prior surgical and medical history.

Laser treatments will occur at approximately 4-8-week intervals depending on what the Burn Center scheduling department allows. For completion of this study, the subject will undergo 6 laser treatments which should take about 6-12 months. During each laser treatment visit, the treated scar will have the drug (bimatoprost) rubbed on top of the scar while the subject is having their surgery. The subject will then continue to apply these drops to their scar for 14 days after the surgery, once in the morning and once at night. The drug will come in a bottle with a dropper top which the subject will apply a couple of drops to their scar and rub it in. The investigators will tell the subject how much drug to apply based on the size of their scar. This drug will be provided to the subject by the research pharmacy and will not be billed to the subject's insurance. The study team will call to remind the subject about their laser visits and to make sure they are applying the ointment for 14 days. The subject will apply the study drug to one scar and the control drug to the other scar. The investigators will label the containers so subjects will know which one to apply where. The subject will write down when they apply their medications in a diary entry that will be completed daily for 14 days after each laser procedures.

While most patients with burn scars undergo 6 treatments, and this is the goal for this study, sometimes depending on how the subject's scar is responding to treatment, they along with their clinical team may decide to stop treatments before the subject gets to 6 treatments, or continue after 6 treatments. Treatments of scars will stop when the clinical team elects to stop laser treatment.

If this means that the subject will only receive 1, 2, 3, 4, or 5 laser treatments instead of 6, then the subject will go into long-term follow up for the study. However, if that means the subject will get more than 6 laser treatments as a part of their clinical care, they will no longer apply the investigational drug after 6 treatments. The subject's laser surgeries will not be any longer because of their participation in the study, they will take the same amount of time as if they were not a study participant.

Treated scars will be assessed at these regular intervals: within 18 days ± 3 days following each treatment, and 12 months ± 1 month after the final study laser treatment. During the 12-month follow-up, there will also be a blood draw where less than 2 tablespoons of blood are collected. The study team will call the subject to remind them about their follow-up visits so that they can make every effort to be there. The follow-up visits will take about 30 minutes-1 hour and will be with a member of the research team. These visits can be scheduled right after the subject will be returning to see their rehab therapist for their post-laser assessment. The subject would have to come back to these follow-ups as a part of their routine clinical care any way if they were not a part of this research study.

A 3mm punch biopsy will be collected from the treatment and control scars at each laser treatment visit (Laser surgery #1, #2, #3, #4, #5, and #6). Two 3mm punch biopsies will be taken of non-burned skin only at the first laser treatment. These biopsies will be taken when the subject is under anesthesia as a part of their laser surgery.

At study entrance and at each study visit, photographs will be taken of the control and treated scars. All photographs taken for the purpose of this study will be taken by a study camera, with images stored on a password-protected secure server. These photographs will be labeled with a study ID number. All efforts will be made to minimize the amount of identifiable information such as the face or tattoos in these photos.

02

Conditions studied

  • Scars
  • Hypopigmented Scar
  • Hypopigmented Skin
  • Burn Scar
  • Scarring
  • Cicatrix, Hypertrophic
  • Cicatrix
  • Pigmentation Disorder
  • Burns Laser

Keywords

  • burn hypertrophic scar
  • burn scar hypopigmentation
  • scar
  • hypopigmentation
  • dyschromia
  • pigmentation abnormality
03

In context

Cicatrix, Hypertrophic Reclassified

129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.

This study's planned enrollment of 25 is below the median of 36 across 106 interventional studies indexed under Cicatrix, Hypertrophic.

Browse Cicatrix, Hypertrophic studies →

Lead sponsor

Medstar Health Research Institute is the lead sponsor of 161 studies on the registry; 31 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.

Compared within Cicatrix, Hypertrophic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cicatrix. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Cutaneous trauma resulting in hypopigmented scar
  3. 2 different hypopigmented scars (at least 30cm2 each) with at least 2 inches of normal skin, hyperpigmented scar, or hypopigmented scar separating each hypopigmented study site scar

Exclusion criteria

Exclusion Criteria

  1. Target hypopigmented scar to face or genitalia
  2. Known allergy to bimatoprost
  3. Known allergy to lidocaine
  4. Positive urine pregnancy test in women of (per point of care test)
  5. Lactating women (self-reported)
  6. Prisoner status
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Treatment

    Bimatoprost will be delivered to the scars using laser-assisted drug delivery in this arm

    Drug: Bimatoprost

  • Sham comparator
    Control

    Saline control will be delivered to the scars using laser-assisted drug delivery in this arm

    Drug: Saline

Interventions

  • Bimatoprost will be delivered with laser

  • DrugSaline

    Saline control will be delivered with laser

06

What researchers measure

Primary outcomes

  1. Area of pigmentation

    area of pigmentation within control and treated scars

    Time frame: follow-up number 6, an average of 8 months

Secondary outcomes

  1. Melanin Index

    Melanin index of hypopigmented burn scars (minimum=500, maximum=950, higher score correlates with a better outcome)

    Time frame: follow-up number 6, an average of 8 months

  2. Differential gene expression of tyrosinase

    pigmentation signaling molecules within tissue punch biopsies

    Time frame: follow-up number 6, an average of 8 months

  3. Differential gene expression of tyrosinase-related protein 1

    pigmentation signaling molecules within tissue punch biopsies

    Time frame: follow-up number 6, an average of 8 months

  4. Differential gene expression of tyrosinase-related protein 2

    pigmentation signaling molecules within tissue punch biopsies

    Time frame: follow-up number 6, an average of 8 months

Other outcomes

  1. Patient and Observer Scar Assessment Scale (POSAS)

    minimum=0, maximum=10, higher score correlates with worse outcomes

    Time frame: follow-up number 6, an average of 8 months

  2. VanCouver Scar Scale

    minimum=0, maximum=13, higher score correlates with worse outcomes

    Time frame: follow-up number 6, an average of 8 months

  3. Non-invasive measurement of melanin

    melanin index value will be obtained using the Delfin Technologies SkinColorCatch Probe

    Time frame: follow-up number 6, an average of 8 months

  4. Non-invasive measurement of elasticity

    instant skin elasticity value will be obtained using the Delfin Technologies Elastimeter Probe

    Time frame: follow-up number 6, an average of 8 months

  5. Non-invasive measurement of stiffness

    stiffness (N/m) value will be obtained using the Checkline Durometer

    Time frame: follow-up number 6, an average of 8 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2023
First posted
Nov 8, 2023
StartActual
Jul 18, 2023
Primary completionEst.
Dec 30, 2024
CompletionEst.
Jul 31, 2025
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06122090
Collaborators
Latham Fund
Responsible party
Bonnie Carney (Research Scientist, Department of Burn Research, Principal Investigator, Medstar Health Research Institute) — Principal investigator
First posted
Nov 8, 2023
Start date
Jul 18, 2023
Primary completion
Dec 30, 2024 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
May 3, 2024

Study contacts

Alison Ross, BA
Contact
fbsrlresearch@medstar.net
202-877-5170

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimatoprost

Start the discussion